Navigation Links
Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
Date:3/18/2008

ard-looking statements involve risks and uncertainties. Kosan's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the uncertain progress and results of Kosan's preclinical and clinical testing, including the risks that studies and trials may not demonstrate safety and efficacy sufficient to initiate clinical trials on the timing currently anticipated, or at all, continue clinical development, obtain the requisite regulatory approvals or result in a marketable product; the conduct of clinical trials; manufacturing; regulatory approval requirements and process; the effort and expense necessary for further development of Kosan's product candidates, including the costs of bortezomib; intellectual property matters, including Kosan's ability to obtain valid and enforceable patents covering its product candidates; Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan's strategy to enter into partnering or licensing arrangements. These and other risk factors are discussed under "Risk Factors" in Kosan's Annual Report on Form 10-K for the year ended December 31, 2007 and other periodic filings with the SEC. Kosan expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
2. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
3. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
4. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
5. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
6. Kosan Announces February 28, 2008 Conference Call and Webcast
7. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
8. Kosan Announces Third Quarter 2007 Financial Results
9. Kosan to Reacquire Epothilone Program From Roche
10. Kosan Biosciences to Host Research & Development Day on October 31, 2007
11. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 With the ability to record continuously ... more than 15 minutes, Fastec Imaging has brought the same ... speed imaging. “Finally, a high speed camera that can be ... our everyday lives.” proclaims Matt Kearney, VP of Sales for ... to demystify and simplify the traditionally complicated workflow of a ...
(Date:7/23/2014)... MD (PRWEB) July 23, 2014 a2z ... and ChirpE Mobile App, AACC Pathfinder, in its ... offerings. AACC’s annual meeting is planned for July 29-31, ... the place to be to connect with global leaders ... lab management, and other areas of breaking science in ...
(Date:7/23/2014)... Astra Nova Training , ... and pharma training services, and the Alliance ... a non-profit integrating the expertise and investments of ... global system for clinical trials, are pleased to ... expertise of industry professionals through improved and easily ...
(Date:7/22/2014)... , July 22, 2014 The Board of Directors ... ) has declared a quarterly dividend of 54.5 cents per ... record on September 9, 2014. The indicated annual dividend rate ... BD is a leading medical technology company that partners ... most pressing and evolving health needs. Our innovative solutions are ...
Breaking Biology Technology:Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 2Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 3
... , Madison, Wis. Battery and household products manufacturer ... St. Louis-based firm United Industries for $1.2 billion dollars of ... in February. The deal will give Rayovac an increased foothold ... such as Spectracide, Vigoro and Sta-Green. , Inacom joins EMC ...
... Spence, a physics graduate student, and Roch Kendrick, a ... clothing while working on equipment used for the Madison ... Photo courtesy of UW-Madison. In an underground bunker ... side, and a cornfield on the other, a team ...
... satellite. Courtesy of UW-Madison. Madison, Wis. ... the University of Wisconsin's Cooperative Institute for Meteorological ... institute has begun testing its weather forecast data using ... Silicon Graphics Inc. , a company headquartered in California ...
Cached Biology Technology:Tech Digest: Rayovac, Inacom, TomoTherapy, Regal-Beloit, Modine 2Earth's core modeled in underground experiment 2Earth's core modeled in underground experiment 3UW-Madison picks scalable SGI computer to simulate weather 2UW-Madison picks scalable SGI computer to simulate weather 3
(Date:7/23/2014)... disease, the devastating neurological disease affecting more than ... new progress on a set of compounds, initially ... a potential oral therapy for Alzheimer,s. Their study ... . , Carlo Ballatore, Kurt R. Brunden and ... protein known as tau binds to and stabilizes ...
(Date:7/23/2014)... and blood-brain barrier damage appear after cerebral ... Matrix metalloproteinase-9 is able to degrade the ... cerebral blood vessels and to mediate extracellular ... colleagues from the First Affiliated Hospital of ... induced cerebral infarction in stroke-prone spontaneously hypertensive ...
(Date:7/23/2014)... is available in German . ... Max Planck Institute of Molecular Cell Biology and ... capture detailed three-dimensional images of cardiac dynamics in ... Plane Illumination Microscopy (SPIM) and clever image processing ... heart. Furthermore, they have developed a method of ...
Breaking Biology News(10 mins):Unbreak my heart 2
... sequence the genome of a microbiological master of ... scientists because they are able to live under ... concentrations, high pH-values, or high temperatures. Nature's masters ... researchers can draw conclusions about the first organisms ...
... Molecular Biology Laboratory (EMBL) in Heidelberg and the Institute ... have now added key evidence to claims that some types ... reported this week in the on-line edition of Nature ... placed in the right locations within stem cells before they ...
... melanoma this year, says the American Cancer Society, and ... caught in the early stages, melanoma can be a ... with an efficiency that few tumors possess. Now, researchers ... of the reasons why this particular skin tumor is ...
Cached Biology News:Life in deadly conditions 2Life in deadly conditions 3A new link between stem cells and tumors 2Researchers discover why melanoma is so malignant 2Researchers discover why melanoma is so malignant 3